PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-304.29%
Negative EBIT growth while AVXL is at 69.57%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
27.06%
Operating income growth under 50% of AVXL's 69.57%. Michael Burry would be concerned about deeper cost or sales issues.
-304.05%
Negative net income growth while AVXL stands at 76.61%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-302.06%
Negative EPS growth while AVXL is at 76.67%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-288.66%
Negative diluted EPS growth while AVXL is at 76.67%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.11%
Share change of 0.11% while AVXL is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
3.68%
Diluted share change of 3.68% while AVXL is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
56.08%
OCF growth above 1.5x AVXL's 1.73%. David Dodd would confirm a clear edge in underlying cash generation.
56.11%
FCF growth above 1.5x AVXL's 1.73%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18524.76%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-17391.51%
Negative 5Y OCF/share CAGR while AVXL is at 83.38%. Joel Greenblatt would question the firm’s operational model or cost structure.
-1778.39%
Negative 3Y OCF/share CAGR while AVXL stands at 91.44%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-42866.91%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-15208.07%
Negative 5Y net income/share CAGR while AVXL is 89.85%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-5247.61%
Negative 3Y CAGR while AVXL is 95.69%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
4590.00%
Equity/share CAGR of 4590.00% while AVXL is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
1682.71%
Positive 5Y equity/share CAGR while AVXL is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
1405.22%
3Y equity/share CAGR above 1.5x AVXL's 57.46%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
247.25%
Positive BV/share change while AVXL is negative. John Neff sees a clear edge over a competitor losing equity.
-50.51%
We’re deleveraging while AVXL stands at 27.09%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-53.09%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
3.56%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.